BioSpace News Archive

STRATA Skin Sciences, Inc. announced it plans to release its fourth quarter and full-year 2023 financial results on Wednesday, March 27, 2024.

IMUNON, Inc. announces it has filed an Investigational New Drug application with the U.S. Food and Drug Administration for IMNN-101 for a Phase 1 clinical study with a seasonal COVID-19 booster vaccine.

Protara Therapeutics, Inc. today announced financial results for the full year and fourth quarter ended December 31, 2023 and provided a business update.

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. today announced its full year 2023 financial results and provided recent operating highlights for the clinical programs in ALS and MS.

Prime Therapeutics LLC/Magellan Rx Management, LLC (Prime), a leading pharmacy solutions organization, and Capital Rx, Inc. (Capital Rx), a renowned health care technology solutions provider, are announcing a strategic alliance.

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.

Kazia Therapeutics Limited is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024.

The Max Foundation and BeiGene today announced that the first doses of BRUKINSA® (zanubrutinib) have been administered for the treatment of adult patients with chronic lymphocytic leukemia (CLL) to patients in Armenia and Nepal, as part of a three-year collaboration to provide access to the medicine in 29 low- and middle-income countries (LMICs).

Affini-T Therapeutics, Inc today announced that preclinical data from its oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held in San Diego, CA.

Autobahn Therapeutics today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024, at 3:30 p.m. ET.